Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a botanical extract increased Bcl-2 levels and improved the anagen-to-telogen hair ratio in men with androgenetic alopecia, suggesting potential for managing chemotherapy-induced alopecia.

This study found that KY19382, a small molecule activating the Wnt/β-catenin pathway, significantly improved wound healing by enhancing cell migration, increasing collagen and stem cell markers, and accelerating re-epithelialization and neo-epidermis formation in a murine model without causing significant cytotoxicity.

In a pilot study with 21 patients, the niostem device increased hair counts and density and enhanced testers’ self-perception of hair growth at 6 months without reported adverse effects, suggesting potential benefits for androgenetic alopecia.

This study found that the ID2 gene was highly expressed in bulge-derived keratinocytes when exposed to contact sensitizers and may serve as a marker to distinguish sensitizers from irritants during in vitro testing.

A new test helps find drugs to treat head and neck cancer by targeting c-Rel.

This study presented a new wearable textile-based device with near-infrared OLEDs that significantly reduced cell aging markers and improved cell migration in vitro, suggesting it as a promising, non-invasive phototherapy option for hair follicle treatment and hair-loss management.

This study reported that the new near-infrared LED device showed significant improvements in skin rejuvenation and a slight increase in hair growth, with further research recommended for broader validation.

This study found that the computer-controlled RV-01 scalp cooling device helped prevent significant hair loss in metastatic breast cancer patients treated with eribulin, with none of the 16 patients requiring a wig and experiencing minimal discomfort.

This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

In preclinical studies, topical CUR61414 reduced Hh signaling and shrank BCCs in mice, but this study found no clinical efficacy in human superficial or nodular BCCs.

This research reported that KDML105 bran extract demonstrated antioxidant activities, reduced nitric oxide production, and influenced gene expression related to the hair cycle in cultured dermal papilla cells, suggesting potential as an anti-hair loss agent by supporting the anagen phase and angiogenesis.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

This study found that VB-1, a vitexin compound, may promote human hair follicle growth by enhancing Wnt/β-catenin signaling in dermal papilla cells.

Among participants in a 26-week trial, this study by REVIAN Inc. reported that their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia was both safe and effective at the 16-week mark.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study suggests that rather than inhibiting IL-15, selectively stimulating IL-15Ra-mediated signaling could be beneficial for managing alopecia areata and possibly other inflammatory hair loss conditions, as IL-15 promoted hair growth and maintained immune privilege in human hair follicles.

This study found that applying a 1% sodium N-(dihydrolipoyl)-l-histidinate zinc complex lotion to the scalp did not prevent chemotherapy-induced alopecia in breast cancer patients, but it may aid recovery.

In this study, researchers established five new immortalized human dermal papilla cell lines from a male with androgenetic alopecia, which may serve as valuable tools for hair research.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study found that recombinant hepatitis B vaccine may increase the risk of alopecia areata onset in older predisposed mice but larger trials suggest this effect might lie within normal variation.

In this study, researchers found that most patients with frontal fibrosing alopecia lacked the protective rs1800440 polymorphism in the CYP1B1 gene, suggesting its potential role in the development of this condition, while a significant number carried the rs9258883 polymorphism in HLA-B*07:02.

This study found that baicalin promotes human microvascular endothelial cell proliferation, while visnadin and minoxidil enhance tubulogenesis, with hesperidin uniquely increasing VEGFR-2 phosphorylation compared to other compounds tested.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study found that lncRNA2919 negatively impacts hair follicle regeneration by decreasing follicle depth and density in a rabbit model, suggesting a regulatory role in the hair follicle cycle through DNA methylation.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.